Collegium Pharmaceutical Inc (COLL.OQ)
24.14USD
7:24pm BST
$-0.53 (-2.15%)
$24.67
$24.64
$24.67
$23.83
33,194
175,143
$29.80
$7.37
About
Overall
Beta: | -- |
Market Cap(Mil.): | $348.59 |
Shares Outstanding(Mil.): | 29.57 |
Dividend: | -- |
Yield (%): | -- |
Financials
COLL.OQ | Industry | Sector | |
---|---|---|---|
P/E (TTM): | -- | 30.95 | 32.74 |
EPS (TTM): | -3.65 | -- | -- |
ROI: | -99.46 | 14.84 | 14.38 |
ROE: | -101.15 | 16.34 | 16.07 |
BRIEF-Collegium Appoints Shirley Kuhlmann As General Counsel
* COLLEGIUM ANNOUNCES THE APPOINTMENT OF SHIRLEY KUHLMANN AS GENERAL COUNSEL Source text for Eikon: Further company coverage:
BRIEF-Collegium Reports Q4 Loss Per Share $0.54
* COLLEGIUM REPORTS FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
BRIEF-Collegium To Host Conference Call To Discuss Fourth Quarter 2017 Financial Results And Provide Corporate Update
* COLLEGIUM TO HOST CONFERENCE CALL TO DISCUSS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:
BRIEF-Collegium Filed Patent Infringement Lawsuit Against Teva Pharma USA
* COLLEGIUM PHARMA SAYS FILED PATENT INFRINGEMENT LAWSUIT IN U.S. DISTRICT COURT FOR DISTRICT OF DELAWARE AGAINST TEVA PHARMACEUTICALS USA INC
BRIEF-Janus Henderson Group Reports 10.1 Pct Passive Stake In Collegium Pharmaceutical
* JANUS HENDERSON GROUP PLC REPORTS 10.1 PERCENT PASSIVE STAKE IN COLLEGIUM PHARMACEUTICAL AS OF DEC 31, 2017 - SEC FILING Source text : [http://bit.ly/2mvIp5l] Further company coverage:
BRIEF-Depomed Announces Closing Of Nucynta Commercialization Agreement With Collegium Pharmaceutical
* DEPOMED ANNOUNCES CLOSING OF NUCYNTA COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL
BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical
* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL
BRIEF-Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical
* DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL
BRIEF-Collegium To License Rights To Commercialize Nucynta Franchise
* COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE
BRIEF-Collegium reports third quarter loss of $0.45 per share
* Collegium reports third quarter financial results and provides corporate update
Competitors
Price | Chg | |
---|---|---|
Pfizer Inc. (PFE.N) | $36.75 | +0.12 |
Teva Pharmaceutical Industries Limited (TEVA.TA) | 6,285.00 | -76.00 |
Endo International PLC (ENDP.OQ) | $5.61 | +0.10 |
Pain Therapeutics, Inc. (PTIE.OQ) | $7.80 | -0.03 |
IntelliPharmaCeutics International Inc. (IPCI.TO) | $0.67 | -0.01 |